Disclosure Plus

COPUS KOREA Co., Ltd. Signs Agreement Regarding Change in Management Control

Park Jung-Soo
2026-06-29 10:05:33
[Edaily Reporter Park Jung-Soo ] COPUS KOREA Co., Ltd.(322780)announced on the 29th that it had signed an agreement with Artist Studio and three other parties regarding a change in management control.
The transferor, largest shareholder Oh Young-seop, and one related party entered into a share purchase agreement on the 26th to sell a portion of their shares to Artist Studio and one other party. The company also decided to transfer management control through a new share issuance (5,716,461 shares) and the issuance of the 5th series of convertible bonds (17.5 billion won). Accordingly, the total consideration for the transfer is 28,199,990,000 won.
Upon completion of all agreements, Artist Studio will be registered as the largest shareholder of COPUS KOREA Co., Ltd. and will secure de facto management control. Through the share purchase agreement and the new share subscription agreement, Artist Studio is set to acquire a total of 2,405,487 shares, representing a 16.37% stake.
Furthermore, if Artist Studio exercises its conversion rights on 5.5 billion won worth of the 17.5 billion won convertible bonds, it will acquire an additional 3,062,360 shares (exercise price: 1,796 won). At that point, the total number of shares Artist Studio will hold will be 5,467,847, representing a 22.38% stake.

Economy

Corporation

IT·Science

Economy

Lisa Su Meets with Jeon Young-hyun for 3 Hours… “Broad Partnership” for Foundry Collaboration

Lisa Su, Chairwoman and CEO of AMD, concluded a meeting lasting over three hours with Jeon Young-hyun, President and CEO of SamsungElectronics and Vice Chairman in charge of the Device Solutions (DS) …
2026-10-07 20:35:47

Corporation

South Korea Enters the 160 Trillion Global Obesity Drug Market… HanmiGlobal Co., Ltd’s “Epe” Becomes First Domestically Developed Drug to Receive Approval

Epfeglenatide, developed by HanmiPharm, has received approval from the Ministry of Food and Drug Safety as the first domestically developed GLP-1-based obesity treatment. With this approval, Korea has…
2026-10-07 19:34:02

IT·Science

A Twist in the Story of the New Drug Rejected by Sanofi… Hanmi’s “Epe” Becomes the First Domestically Developed GLP-1 Weight-Loss Drug to Receive Approval

A new domestically developed drug has emerged to compete in the obesity treatment market, which is currently dominated by global pharmaceutical companies. With HanmiPharm’s efeglenatide receiving mark…
2026-10-07 18:22:02